TRVI - Trevi Therapeutics GAAP EPS of -$0.28 misses by $0.03
Trevi Therapeutics press release (NASDAQ:TRVI): Q4 GAAP EPS of -$0.28 misses by $0.03. As of December 31, 2021, the Company had total cash and cash equivalents of $36.8 million.
For further details see:
Trevi Therapeutics GAAP EPS of -$0.28 misses by $0.03